Corpus Intelligence IC Memo — HARVARD MEMORIAL HOSPITAL 2026-04-27 00:04 UTC
IC Memo — HARVARD MEMORIAL HOSPITAL
Investment Committee Memorandum | IL | 13 beds | Grade C | EBITDA uplift $2.2M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 141335

HARVARD MEMORIAL HOSPITAL

LOCATIONMC HENRY, IL·BEDS13·AS OFApril 27, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

HARVARD MEMORIAL HOSPITAL is a 13-bed rural/critical access in MC HENRY, IL with $30.4M in net patient revenue and a 12.5% operating margin. The hospital serves a payer mix of 46.5% Medicare, 2.5% Medicaid, and 51.0% commercial.

Thesis: Turnaround. Our ML models identify $2.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 12.5% to 19.8% (+736bps).

Net Revenue HCRIS$30.4M
Current EBITDA COMPUTED$3.8M
Operating Margin COMPUTED12.5%
Occupancy HCRIS12.8%
Revenue / Bed COMPUTED$2.3M
Net-to-Gross HCRIS36.5%
Distress Probability ML55.9%

2. Market Context & Competitive Position

208
IL Hospitals
-5.3%
State Median Margin
53
Comparable Hospitals

IL has 208 Medicare-certified hospitals with a median operating margin of -5.3%. The target's margin of 12.5% places it above the state median. Among 53 size-comparable peers (6-26 beds), the median margin is -0.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (6-26), prioritizing same-state peers. 53 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HARVARD MEMORIAL HOSPITAL (Target)IL13$30.4M12.5%
GIBSON AREA HOSPITAL AND HEALTIL25$125.0M-6.7%
PARIS COMMUNITY HOSPITALIL25$100.7M-4.2%
SAINT JOSEPH MEMORIAL HOSPITALIL25$86.0M33.9%
WABASH GENERAL HOSPITALIL25$71.8M4.5%
HOOPESTON COMMUNITY MEMORIAL HIL22$71.5M-5.2%
CRAWFORD MEMORIAL HOSPITALIL25$67.7M2.9%
ST. FRANCIS HOSPITALIL25$61.6M17.4%
LINCOLN MEMORIAL HOSPITALIL25$61.5M14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$639K+210bp18mo
Cost to Collect4.5%2.5%$608K+200bp12mo
Denial Rate Reduction12.0%6.5%$602K+198bp12mo
A/R Days Reduction5200.0%3800.0%$370K+122bp9mo
Clean Claim Rate88.0%96.0%$19K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$639K
Cost to Collect
$608K
Denial Rate Reduction
$602K
A/R Days Reduction
$370K
Clean Claim Rate
$19K
Total EBITDA Uplift$2.2M
Current EBITDA$3.8M
+ RCM Uplift+$2.2M
Pro Forma EBITDA$6.0M
Current Margin12.5%
Pro Forma Margin19.8%
WC Released (1x)$1.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$5.8M$47.4M8.12x52.0%
Base (11x exit)10.0x11.0x$5.8M$54.0M9.26x56.1%
Bull Case9.0x11.0x$5.2M$63.3M12.06x64.5%
Bull (12x exit)9.0x12.0x$5.2M$70.6M13.45x68.2%
Bear Case11.0x10.0x$6.4M$34.3M5.35x39.8%
Bear (11x exit)11.0x11.0x$6.4M$39.8M6.21x44.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 12.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 55.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 53 hospitals with 6-26 beds
  • Same-state prioritization (n=54)
  • Comp margins: P25=-5.9% / P50=-0.4% / P75=8.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 27, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.